Antineoplastic Agents

"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Substances that inhibit or prevent the proliferation of NEOPLASMS.

Descriptor ID	D000970
MeSH Number(s)	D27.505.954.248
Concept/Terms	Antineoplastic Agents Antineoplastic Agents Agents, Antineoplastic Antineoplastic Drugs Drugs, Antineoplastic Antineoplastics Chemotherapeutic Anticancer Drug Drug, Chemotherapeutic Anticancer Antitumor Drugs Drugs, Antitumor Cancer Chemotherapy Agents Agents, Cancer Chemotherapy Chemotherapy Agents, Cancer Cancer Chemotherapy Drugs Chemotherapy Drugs, Cancer Drugs, Cancer Chemotherapy Chemotherapeutic Anticancer Agents Agents, Chemotherapeutic Anticancer Anticancer Agents Agents, Anticancer Antitumor Agents Agents, Antitumor

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.

Bar chart showing 445 publications over 30 distinct years, with a maximum of 31 publications in 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1994	0	1	1
1995	1	0	1
1996	1	0	1
1997	0	1	1
1998	3	0	3
1999	0	1	1
2000	2	2	4
2001	0	1	1
2002	3	1	4
2003	9	2	11
2004	6	1	7
2005	6	4	10
2006	15	4	19
2007	8	7	15
2008	12	7	19
2009	16	2	18
2010	16	14	30
2011	17	8	25
2012	16	14	30
2013	14	7	21
2014	22	9	31
2015	21	8	29
2016	13	12	25
2017	23	7	30
2018	16	5	21
2019	14	8	22
2020	16	6	22
2021	15	6	21
2022	6	1	7
2023	15	0	15

Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.

Firestone R, Lesokhin AM, Usmani SZ. An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma. Blood Cancer Discov. 2023 Nov 01; 4(6):433-436.

View in: PubMed
Mukhopadhyay D, Goel HL, Xiong C, Goel S, Kumar A, Li R, Zhu LJ, Clark JL, Brehm MA, Mercurio AM. The calcium channel TRPC6 promotes chemotherapy-induced persistence by regulating integrin a6 mRNA splicing. Cell Rep. 2023 Nov 28; 42(11):113347.

View in: PubMed
Manojlovich M, Blok A, Wright N, Azhari E, Farris KB, Friese CR, Mackler E, Titler M, Byrnes M. Photo elicitation, an approach to better understanding the patient experience with OAAs: pilot study and future implications. Support Care Cancer. 2023 Oct 25; 31(12):652.

View in: PubMed
Xue T, Fei S, Gu J, Li N, Zhang P, Liu X, Thompson PR, Zhang X. Inhibiting MEK1 R189 citrullination enhances the chemosensitivity of docetaxel to multiple tumour cells. Philos Trans R Soc Lond B Biol Sci. 2023 11 20; 378(1890):20220246.

View in: PubMed
Devarajan P, Vong AM, Castonguay CH, Silverstein NJ, Kugler-Umana O, Bautista BL, Kelly KA, Luban J, Swain SL. Cytotoxic CD4 development requires CD4 effectors to concurrently recognize local antigen and encounter type I IFN-induced IL-15. Cell Rep. 2023 10 31; 42(10):113182.

View in: PubMed
Miao X, Wu LS, Lin SXW, Xu Y, Chen Y, Iwaki Y, Kobos R, Stephenson T, Kemmerer K, Uhlar CM, Banerjee A, Goldberg JD, Trancucci D, Apte A, Verona R, Pei L, Desai R, Hickey K, Su Y, Ouellet D, Samtani MN, Guo Y, Garfall AL, Krishnan A, Usmani SZ, Zhou H, Girgis S. Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1. Target Oncol. 2023 09; 18(5):667-684.

View in: PubMed
Arun Kumar S, Gao J, Patel SA. The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma. Leuk Res. 2023 Nov; 134:107385.

View in: PubMed
Gao J, Dahiya S, Patel SA. Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas. Br J Haematol. 2023 10; 203(2):161-168.

View in: PubMed
Lonial S, Bowser AD, Chari A, Costello C, Krishnan A, Usmani SZ. Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 11; 23(11):815-824.

View in: PubMed
Moreau P, van de Donk NW, Nahi H, Oriol A, Nooka AK, Martin T, Rosinol L, Karlin L, Benboubker L, Mateos MV, Popat R, Mart?nez-L?pez J, Sidana S, Delforge M, Pei L, Trancucci D, Olyslager Y, Uhlar C, Stephenson T, Rampelbergh RV, Banerjee A, Kobos R, Usmani SZ. Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma. Future Oncol. 2023 Apr; 19(12):811-818.

View in: PubMed

People

Explore

Similar Concepts

Top Journals